arrow
M

Marco L. Davila

h lee moffitt cancer center
H指数:44
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prophylaxis with dexamethasone or anakinra in patients with high-risk large B cell lymphoma treated with axicabtagene ciloleucel

在高风险大B细胞淋巴瘤患者中使用地塞米松或阿那白滞素进行预防性治疗,这些患者接受阿西美珠单抗治疗

2026-09-270
PRE
System-level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated With High One-year Survival and Reduced Cost

异基因造血细胞移植项目的系统级重组与高一年生存率和降低成本相关

2026-07-050
OAAI
IFN-γ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy

煽风点火:IFN-γ加剧CAR-T炎症和血细胞减少。jci.org SR Bailey, MV Maus

2026-01-021
PRE
Cre-dependent gene expression enables thymic development of autoreactive tumor associated antigen targeting chimeric antigen receptor T cells

Cre依赖性基因表达使能够靶向自体反应性肿瘤相关抗原的嵌合抗原受体T细胞在胸腺中发育。

2025-12-240
PRE
IL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity

IL-36γ装甲CAR T细胞重编程中性粒细胞以诱导内源性抗肿瘤免疫

2025-12-110
PRE
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies

关于未来早期CAR T疗法研究中定义嵌合抗原受体T细胞(CAR T)剂量限制性毒性(DLTs)的建议

2025-11-070
PRE
ICANS and mortality after CAR-T therapy for NHL patients can be predicted using physical function measures of falls, balance and strength deficits, and use of an assistive device

ICANS和NHL患者CAR-T疗法后的死亡率可以通过跌倒、平衡和力量缺陷等身体功能指标以及辅助设备的使用情况进行预测。

2025-09-180
PRE
Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

静脉免疫球蛋白(IVIG)用于与嵌合抗原受体T细胞(CAR-T)疗法相关的严重神经毒性患者

2025-04-210
OA
Intrinsic Tumor Drivers and Immune Escape Mechanisms in CD19 CAR T-Cell Therapy Resistance for Aggressive Large B Cell Lymphoma

内在肿瘤驱动因素和免疫逃逸机制在侵袭性大B细胞淋巴瘤的CD19 CAR T细胞疗法耐药性中的作用

BLOOD
IF23.1
2024-11-051
PRE
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
2024-01-087
OAAI